UK Households Could Be £5,000 Richer With More Innovation, Brown Says
Former PM Gordon Brown argues Britain's research strengths are not translating into economic gains, calling for innovation at the core of policy.
Britain's households could each be £5,000 wealthier if the country did a better job converting its world-class research base into globally competitive companies, former Prime Minister Gordon Brown argued ahead of the Innovation Nation Conference in Manchester Monday.
Brown, who led the UK government from 2007 to 2010, contends that the next decade is poised to deliver the most significant scientific breakthroughs in roughly a century, driven by advances in artificial intelligence, quantum computing and biology. He argues Britain risks being a bystander rather than a beneficiary unless innovation is moved to the center of government strategy.
Read more Coogan and Burnham Back Plan to Revive Middleton, Near Manchester →
The UK's research credentials are substantial. The country is home to four of the world's top 10 universities and 16 of the top 100, with five ranking among Europe's leading institutions for spin-outs — startups built on university-generated intellectual property. Despite representing less than one percent of global population, the UK accounts for six percent of the world's research papers, nearly nine percent of citations, and twelve percent of the most highly cited work.
Yet Brown's central concern is a persistent gap between scientific output and commercial scale. Britain has historically struggled to grow small companies into global success stories, ceding ground to the United States and China, which he describes as the world's dominant innovation powerhouses. The conference, also addressed by Greater Manchester Mayor Andy Burnham and Prime Minister Keir Starmer, focused on how to close that gap.
The debate arrives at a moment when governments worldwide are racing to capture economic gains from AI-driven productivity, clean energy and next-generation healthcare. Brown frames the stakes in human terms — treatments for cancer and dementia, solutions to antibiotic resistance — as well as economic ones. Continue reading at Business | The Guardian.
